Gelteq Limited stock jumps in premarket after CBD gel study; what’s next for GELS
Gelteq shares soared 48% to $1.23 in premarket trading after preclinical data showed its oral gel increased CBD absorption by over 22% versus an FDA-approved oil. The company said the findings could speed up its medicinal cannabis launch in Australia. The stock’s small market cap has amplified volatility. The results have not yet been tested in humans.
